ClinicalTrials.gg
RecruitingNCT03571568Updated Oct 2, 2026

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

A Phase 1/2 interventional study of BI-1206 and Rituximab in Indolent B-Cell Non-Hodgkin Lymphoma, sponsored by BioInvent International AB. Recruiting at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by BioInvent International AB · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2018; still recruiting 8 years 6 months later.
Updated Oct 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Read the detailed description

This is a Phase 1/2a, multicenter, dose escalation, consecutive-cohort, open-label trial of BI-1206 in combination with rituximab with or without acalabrutinib in subjects with indolent relapsed or refractory B-cell NHL, sub-types FL (except FL grade 3B), MZL, and MCL.

Phase 2a, consists of signal seeking cohorts followed by a randomized, parallel, two-arm dose optimization.

The trial consists of 2 main parts:

Phase 1

- Dose Escalation, with two different Arms assessing IV or SC dosing of BI-1206 in combination with rituximab, with dose escalation cohorts and selection of the IV and SC doses of BI-1206 for Phase 2a

Phase 2a

  • Dose Expansion, with one expansion cohort evaluating the selected IV dose of BI-1206 in combination with rituximab
  • Signal Seeking, assessing IV and SC dosing of BI-1206 in combination with rituximab and acalabrutinib. The Signal Seeking will consist of a Safety Run-in and an Expansion
  • Dose Optimization to select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib
02

Conditions studied

  • Indolent B-Cell Non-Hodgkin Lymphoma
03

In context

Lead sponsor

BioInvent International AB is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are ≥ 18 years of age by initiation of study treatment.
  2. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)
  3. Have measurable nodal disease
  4. Are willing to undergo lymph node or biopsies of other involved tissue
  5. Have disease or disease refractory to conventional treatment or for which no standard therapy exists
  6. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen
  7. Have a of at least 12 weeks
  8. Have an (ECOG) performance status of 0-2
  9. Have CD20+
  10. Have hematological and biochemical indices within prespecified ranges

Exclusion criteria

Exclusion Criteria:

  1. Have had an allogenic bone marrow or stem cell transplant within 12 months
  2. Have presence of active chronic
  3. Have current lymphoma or compromise of the central nervous system
  4. Have transformed lymphoma from a pre-existing indolent lymphoma
  5. Have Waldenstrom's Macroglobulinemia or FL grade 3B,
  6. Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other ) while on the study trial other than as pre-medication.
  7. Have known or suspected to rituximab or BI-1206
  8. Have cardiac or renal amyloid light-chain amyloidosis
  9. Have received any of the following:

    1. Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206
    2. Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks
    3. Immunotherapy within 8 weeks
    4. containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib
  10. Have ongoing toxic manifestations of previous treatments.
  11. Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).
  12. Have had major surgery from which the subject has not yet recovered.
  13. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.
  14. Are serologically positive for , or (HIV).
  15. Have an active, known or suspected disease.
  16. Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease ( [NYHA])
  17. Have current of other types
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    BI-1206 IV Dose Escalation

    Standard 3+3 Dose-Escalation of BI-1206 IV in combination with Rituximab

    Biological: BI-1206 · Biological: Rituximab

  • Experimental
    BI-1206 SC Dose Escalation

    Adaptive Dose Escalation of BI-1206 SC (Bayesian logistic regression model (BLRM) in combination with Rituximab

    Biological: BI-1206 · Biological: Rituximab

  • Experimental
    Phase 2a IV Dose expansion

    BI-1206 IV in Combination with Rituximab

    Biological: BI-1206 · Biological: Rituximab

  • Experimental
    Phase 2a SC Signal seeking

    SC Arm, BI-1206 in Combination with Rituximab and Acalabrutinib

    Biological: BI-1206 · Biological: Rituximab · Biological: Acalabrutinib

  • Experimental
    Phase 2a IV Signal Seeking

    IV Arm, BI-1206 in Combination with Rituximab and Acalabrutinib

    Biological: BI-1206 · Biological: Rituximab · Biological: Acalabrutinib

Interventions

  • BiologicalBI-1206

    BI-1206 150 mg / 225 mg Subcutaneous injection BI-1206 50 mg /100 mg Intravenous infusion

  • BiologicalRituximab

    Rituximab 375 mg/m2, as per SmPC

    Also known as: Ruxience

  • BiologicalAcalabrutinib

    Acalabrutinib 100 mg orally as per SmPC

    Also known as: Calquence

06

What researchers measure

Primary outcomes

  1. Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab and/or acalabrutinib

    Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab or rituximab and acalabrutinib in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), subtypes follicular lymphoma (FL)(except FL grade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Assessment will be done according to National Cancer Institute (NCI-CTCAE) criteria v. 5.0.

    Time frame: During the 28-day treatment period on induction therapy

  2. Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)

    Phase 1: Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab.

    Time frame: During the 28-day treatment period on induction therapy

  3. Determine the recommended dose of BI-1206 in combination with rituximab and acalabrutinib

    Phase 2a: Select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib.

    Time frame: During the 28-day treatment period on induction therapy

Secondary outcomes

  1. Evaluation of PK parameters for BI-1206

    PK parameters assessed will include AUC, Cmax, time to Cmax and t1/2 of BI-1206 when administered IV or SC

    Time frame: Up to 1 year

  2. Evaluation of ADA (immunogenicity) response to BI-1206

    Assess the incidence and titre of antidrug antibodies of BI-1206 in serum when administered IV or SC in combination with rituximab or rituximab and acalabrutinib.

    Time frame: Up to 1 year

  3. Measurement of peripheral blood B-lymphocytes depletion

    Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib measuring B Lymphocytes CD19+ (absolute value) as part of hematology assessment to determine the level of peripheral blood B lymphocyte depletion.

    Time frame: Up to 1 year

  4. Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).

    Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy.

    Time frame: Up to 1 year

Other outcomes

  1. Expression levels of CD32b protein

    To investigate CD32b protein expression levels using flow cytometry to evaluate any potential correlation with clinical responses. Change from baseline expression levels will be summarized descriptively by dose cohort and/or response to treatment.

    Time frame: Up to 1 year

  2. Assessment of Patient Reported Outcomes using the NCI PRO-CTCAE questionnaire

    The NCI PRO-CTCAE will be used to evaluate symptomatic toxicities reported by patients. The questionnaire characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities, all toxicities that can be meaningfully reported from the patient perspective. Responses are scored from 0 to 4 (or 0/1 for absent/present). Scores for each attribute (frequency, severity and/or interference) will be presented descriptively (e.g. summary statistics or graphical presentations).

    Time frame: Up to 1 year

  3. Expression levels of CD32b and/or other immunological markers

    Perform whole-transcriptome, quantitative polymerase chain reaction (qPCR) and/or IHC analysis of lymph node biopsies to evaluate potential correlation with clinical responses.

    Time frame: Up to 1 year

  4. Measurement of serum cytokines levels and/or soluble CD32b.

    Study the potential cause of infusion related reactions (IRRs), such as cytokine release signs, C-reactive protein (CRP) and/or soluble CD32b.

    Time frame: Up to 1 year

07

Study locations

13 of 27 sites recruiting
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405
    Louisville, Kentucky 40207, United States
    Recruiting
    • Don Stevens, MD · Principal investigator
  • Hospital São Rafael
    Salvador, Estado de Bahia, Brazil
    Recruiting
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting
  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
    Curitiba, Brazil
    Not yet recruiting
  • Ruschel Medicina e Pesquisa Clínica
    Rio de Janeiro, Brazil
    Not yet recruiting
  • A.C. Camargo Cancer Center
    São Paulo, Brazil
    Recruiting
  • Hospital Amaral Carvalho
    São Paulo, Brazil
    Not yet recruiting
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, Brazil
    Not yet recruiting
  • Hospital Israelita Albert Einstein
    São Paulo, Brazil
    Recruiting
  • Hospital Samaritano
    São Paulo, Brazil
    Not yet recruiting
  • Hospital Sírio-Libanês
    São Paulo, Brazil
    Not yet recruiting
  • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie
    Frankfurt am Main, Hesse, Germany
    Not yet recruiting
  • Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care
    Stuttgart, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Szpital Specjlistyczny
    Grudziądz, 86-300, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Małopolskie Centrum Medyczne
    Krakow, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital ICO, Trias i Pujol
    Badalona, Barcelona, Spain
    Recruiting
  • Hospital de la Santa Creu i Sant Pau, Dep Hematologia
    Barcelona, Barcelona, Spain
    Recruiting
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona, Spain
    Recruiting
  • Hospital General Universitario Gregorio Marañon-Oncología Médica
    Madrid, Madrid, Spain
    Recruiting
  • Hospital Universitario HM Sanchinarro
    Madrid, Madrid, Spain
    Recruiting
  • Hospital Universitario Virgen de la Arrixaca
    Murcia, Murcia, Spain
    Not yet recruiting
  • Hospital University Virgen Macarene
    Seville, Seville, Spain
    Recruiting
  • Institut Català d'Oncologia, L'Hospitalet de Llobregat
    Barcelona, Spain
    Recruiting
  • University Hospital Fundacion Jimenez Diaz
    Madrid, Spain
    Recruiting
  • Department of Oncology, Academical Hospital
    Uppsala, Sweden 751 85, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Department of Oncology, Skåne University Hospital
    Lund, SE-22185, Sweden
    Terminated

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.

Supporting information: Study protocol, Clinical study report

Time frame: Within one year from end of study

Access criteria: Paper copy of CSR

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2018 (actual). Primary completion is estimated for Sep 2027, 112 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2018
First posted
Jun 27, 2018
StartActual
May 16, 2018
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added, 13 sites removed
Show 13 added (6 Spain, 4 Brazil, 1 Germany, 1 Poland, 1 Sweden)
  • Hospital São Rafael · Salvador, Brazil
  • Hospital de Clínicas de Porto Alegre · Porto Alegre, Brazil
  • Ruschel Medicina e Pesquisa Clínica · Rio de Janeiro, Brazil
  • Hospital Amaral Carvalho · São Paulo, Brazil
  • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie · Frankfurt am Main, Germany
  • Szpital Specjlistyczny · Grudziądz, Poland
  • Hospital de la Santa Creu i Sant Pau, Dep Hematologia · Barcelona, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon-Oncología Médica · Madrid, Spain
  • Hospital Universitario HM Sanchinarro · Madrid, Spain
  • Hospital Universitario Virgen de la Arrixaca · Murcia, Spain
  • Hospital University Virgen Macarene · Seville, Spain
  • Department of Oncology, Academical Hospital · Uppsala, Sweden
Show 13 removed
  • Hospital São Rafael · Salvador, Brazil
  • Hospital de Clínicas de Porto Alegre · Porto Alegre, Brazil
  • Ruschel Medicina e Pesquisa Clínica · Rio De Janeiro, Brazil
  • Hospital Amaral Carvalho · Sao Paulo, Brazil
  • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie · Frankfurt, Germany
  • Szpital Specjlistyczny · Grudziadz, Poland
  • Hospital de la Santa Creu i Sant Pau, Dep Hematologia · Barcelona, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon-Oncología Médica · Madrid, Spain
  • Hospital Universitario HM Sanchinarro · Madrid, Spain
  • Hospital Universitario Virgen de la Arrixaca · Murcia, Spain
  • Hospital University Virgen Macarene · Seville, Spain
  • Department of Oncology, Academical Hospital · Uppsala, Sweden
Oct 2, 2026
Primary completion
Sep 30, 2026→Sep 30, 2027
Oct 2, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Oct 2, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • A.C. Camargo Cancer Center · São Paulo, BrazilContact a•••@accamargo.org.br→a•••@accamargo.org.br
  • Hospital Israelita Albert Einstein · São Paulo, BrazilContact g•••@gmail.com→g•••@gmail.com
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    13 sites added, 13 sites removed
    Show 13 added (6 Spain, 4 Brazil, 1 Germany, 1 Poland, 1 Sweden)
    • Hospital São Rafael · Salvador, Brazil
    • Hospital de Clínicas de Porto Alegre · Porto Alegre, Brazil
    • Ruschel Medicina e Pesquisa Clínica · Rio de Janeiro, Brazil
    • Hospital Amaral Carvalho · São Paulo, Brazil
    • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie · Frankfurt am Main, Germany
    • Szpital Specjlistyczny · Grudziądz, Poland
    • Hospital de la Santa Creu i Sant Pau, Dep Hematologia · Barcelona, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañon-Oncología Médica · Madrid, Spain
    • Hospital Universitario HM Sanchinarro · Madrid, Spain
    • Hospital Universitario Virgen de la Arrixaca · Murcia, Spain
    • Hospital University Virgen Macarene · Seville, Spain
    • Department of Oncology, Academical Hospital · Uppsala, Sweden
    Show 13 removed
    • Hospital São Rafael · Salvador, Brazil
    • Hospital de Clínicas de Porto Alegre · Porto Alegre, Brazil
    • Ruschel Medicina e Pesquisa Clínica · Rio De Janeiro, Brazil
    • Hospital Amaral Carvalho · Sao Paulo, Brazil
    • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie · Frankfurt, Germany
    • Szpital Specjlistyczny · Grudziadz, Poland
    • Hospital de la Santa Creu i Sant Pau, Dep Hematologia · Barcelona, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañon-Oncología Médica · Madrid, Spain
    • Hospital Universitario HM Sanchinarro · Madrid, Spain
    • Hospital Universitario Virgen de la Arrixaca · Murcia, Spain
    • Hospital University Virgen Macarene · Seville, Spain
    • Department of Oncology, Academical Hospital · Uppsala, Sweden
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • A.C. Camargo Cancer Center · São Paulo, BrazilContact a•••@accamargo.org.br→a•••@accamargo.org.br
    • Hospital Israelita Albert Einstein · São Paulo, BrazilContact g•••@gmail.com→g•••@gmail.com
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03571568
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
May 16, 2018
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Erika Bågeman
Contact
erika.bageman@bioinvent.com
+46706126618
Andres McAllister, MD, PhD
Contact
andres.mcallister@bioinvent.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BI-1206 · Rituximab

Start the discussion